Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated with Chemoradiotherapy: A Brief Report
JTO clinical and research reports（2022）
关键词
Advanced non–small cell lung cancer,Durvalumab,Adjuvant,Immune checkpoint inhibitors,Immune-related toxicity
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要